Go to Health Care Provider version
| Diagnosis | Sarcoma | Study Status | Open |
| Phase | I/II |
| Age | ≥ 12 years of age | Randomisation | YES |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | Biological: Ris-Rez (IV) |
| Last Posted Update | 2026-07-24 |
| ClinicalTrials.gov # | NCT07602777 |
International Sponsor
GlaxoSmithKlinePrincipal Investigators for Canadian Sites
AYA:
McGill University Health Centre - Dr. Saleh
Princess Margaret Cancer Centre (AYA) - Dr. RazakCentres
Study Description
The main goal of this study is to test a new medicine called Risvutatug Rezetecan (Ris-Rez). Researchers want to find out if it can help treat certain types of cancer, if it is safe, how well people tolerate it, and how the body absorbs and breaks down the medicine. This study is for teenagers and adults with osteosarcoma, a type of bone cancer, or soft tissue sarcoma, a type of cancer that starts in soft tissues like muscles, fat, or nerves.
Inclusion Criteria
- Participants must be 12 years of age or older
- Participants must have osteosarcoma (bone cancer) or a soft tissue sarcoma that cannot be removed with surgery or has spread to other parts of the body
- Recent scans must show that the cancer has continued to grow despite the most recent treatment.
- Participants should be well enough to carry out most daily activities and their overall health should have remained stable during the two weeks before starting the study.
- Participants must meet organ and lab function requirements
- Participants (or a parent/legal guardian) must read, understand, and sign a consent form and agree to follow the study requirements before joining.
Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.
